Drug Profile
Research programme: biosimilars - BioFactura
Latest Information Update: 03 Jan 2024
Price :
$50
*
At a glance
- Originator BioFactura
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 03 Jan 2024 Preclinical studies for biosimilars for treatment of unspecified indications is ongoing in the US (Biofactura Pipeline, January 2024)
- 03 Jan 2024 Biofactura plans a clinical trial for one of the biosimilar candidates for the treatment of unspecified indications (Biofactura Pipeline, January 2024)
- 01 Oct 2020 Momenta Pharmaceuticals has been acquired by Johnson & Johnson